Rasagiline 1 mg Tablets (Rasagiline Mesilate)

Adult dose

This medicine is administered orally to adults once daily as monotherapy or adjunctive therapy. 1) Monotherapy or adjunctive therapy with a dopamine agonist: Administer 1mg orally once daily. 2) Adjunctive therapy with levodopa: The recommended initial dose for patients taking levodopa is 0.5mg once daily. If well tolerated and the clinical response is insufficient, the dose may be increased to 1mg once daily. This medicine may be taken with or without food.

This medication should not be administered to certain patients. Individuals allergic to the active ingredient or other components of this medication should not take it. Furthermore, patients on other MAO inhibitors or natural medications taken without a prescription, or those that have stopped such medications within the last two weeks, should not use this drug. Patients who are currently taking, or who have recently stopped taking medications such as pethidine, tramadol, or dextromethorphan within the last two weeks should also avoid this drug. It is contraindicated in patients with moderately severe to severe liver impairment. Various side effects may occur with this medication; common side effects include headache, dizziness, depression, hallucinations, muscle pain, joint pain, nausea, constipation, dry mouth, insomnia, etc. Serious symptoms, such as myocardial infarction or cerebrovascular incidents, may rarely occur, so caution is necessary. This drug may increase the likelihood of motor symptoms, hypotension, or excessive drowsiness when taken with other dopaminergic treatments, so it should be taken under medical supervision. Especially, activities requiring alertness such as driving or operating machinery should be avoided if drowsiness or sleeping spells occur. This medication has a high risk of interactions with other drugs, especially MAO inhibitors, antidepressants, and sympathomimetics, which can lead to serious side effects, so consulting a specialist is essential. Pregnant or breastfeeding women should exercise caution when using this drug, and safety has not been established for children under the age of 18. In case of overdose, severe symptoms may emerge, necessitating immediate medical attention for appropriate treatment. This medication should be stored out of reach of children and kept in a closed container at temperatures between 1–25 degrees Celsius, and should not be transferred to other containers.

Influenza

This medication should be stored in a tightly closed container to protect it from air and moisture. A cool place with a storage temperature between 1 and 25 degrees Celsius is appropriate.

Appearance

White or nearly white flat round tablets with edges

Package unit

30 tablets/bottle, 100 tablets/bottle